Healthcare Industry News: Draeger Medical
News Release - September 8, 2010
XDx Appoints New Vice President of Corporate Development and Legal AffairsBRISBANE, Calif.--(Healthcare Sales & Marketing Network)--XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced that it has appointed Matthew J. Meyer as its Vice President of Corporate Development and Legal Affairs.
“We believe that Mr. Meyer’s experience at larger public and emerging-growth private life sciences companies will immediately benefit our business development and partnering activities, which will build on the recent positive results from the IMAGE Study for XDx’s AlloMap® and the inclusion of AlloMap for the non-invasive monitoring of acute cellular rejection in the inaugural International Society for Heart & Lung Transplantation Guidelines for the care of heart transplant recipients,” said Pierre Cassigneul, President and Chief Executive Officer of XDx. “Mr. Meyer’s wide-ranging domestic and international expertise in business development, licensing, marketing and corporate law will be invaluable as we continue to build our leadership position in molecular diagnostics and we are delighted to welcome him to the team.”
“I am excited to join XDx. I look forward to expanding our strategic relationships with key life science partners, which will allow us to advance new gene expression diagnostic tests, ultimately bringing them to patients,” said Mr. Meyer.
Prior to joining XDx, Mr. Meyer was the Vice President of Business Development and General Counsel at Cerimon Pharmaceuticals, a privately held pharmaceutical company focused on the development of prescription products for pain and inflammation. Prior to that, he held senior management positions at Draeger Medical Systems, the U.S. subsidiary of the German-based global medical device company, most recently serving as Vice President and General Counsel. Prior to Draeger, Mr. Meyer held positions of increasing responsibility at Novartis Pharma AG in Basel, Switzerland, including serving as Head of Global Marketing Channel Innovations. Previously, he was the Vice President, Global Business Development and Legal Affairs at Allscripts’ Physician’s Interactive Division and spent five years as a commercial attorney at Pfizer Inc, working in New York, Connecticut and the United Kingdom.
Mr. Meyer graduated cum laude and Phi Beta Kappa with a Bachelor of Arts degree from Cornell University. He earned his Juris Doctor degree from Villanova University School of Law.
XDx, based in Brisbane, Calif., is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMap® Molecular Expression Testing, an FDA-cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx’s noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases. For more information, please visit www.xdx.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.